Post-Traumatic Stress Disorder | Post-Traumatic Stress Disorder (PTSD) and Seroquel
Post-Traumatic Stress Disorder research study
What is the primary objective of this study?
This 8 weeks study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD.
Who is eligible to participate?
Inclusion Criteria: - Provision of written informed consent - Fluency in English - A diagnosis of PTSD - No pregnancy - Right-handedness Exclusion Criteria: - Pregnancy or lactation - Any cognitive impairment that precludes informed consent - Known intolerance or lack of response to Seroquel - Previous enrollment or randomization of treatment in the present study - Participation in another drug trial within 4 weeks prior enrollment into this study - Patients with Diabetes Mellitus - History of allergic reaction or hypersensitivity to Seroquel - Contraindications to magnetic resonance imaging - Treatment with an effective medication for PTSD
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Post-Traumatic Stress Disorder
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Drug:SeroquelThis study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
SeroquelThis study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD
Start Date: February 2010
Completed Date: March 2015
Primary Outcome: Change From Baseline in PTSD Symptomatology at the Week 8 Timepoint.
Study sponsors, principal investigator, and references
Principal Investigator: Igor Elman, MD
Lead Sponsor: Cambridge Health Alliance